PARP inhibitors are the most extensively studied class of DDR inhibitors, and several PARP inhibitors have been approved for the treatment of ovarian and breast cancers by various regulatory officials, including the United States Food and Drug Administration and the European Medicines Agency. The gene discussed is PARP1; the disease is breast carcinoma.